Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD3 | Q99594 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6119882 | 0.90 | TSHR (0.47) | TEAD3TSHRSMN1; SMN2HTTHRH4 | |
| SCHEMBL24027554 | 0.82 | EPHX2 (0.48) | TEAD3TSHRSMN1; SMN2HTTEPHX2 | |
| SCHEMBL9177436 | 0.80 | TSHR (0.50) | TSHRSMN1; SMN2HTTL3MBTL1TDP1 | |
| SCHEMBL721274 | 0.79 | EPHX2 (0.48) | TEAD3TSHRSMN1; SMN2HTTEPHX2 | |
| SCHEMBL27691549 | 0.78 | L3MBTL1 (0.42) | TEAD3TSHREPHX2L3MBTL1TDP1 | |
| SCHEMBL4663055 | 0.78 | L3MBTL1 (0.50) | TEAD3TSHRSMN1; SMN2HTTHRH4 | |
| SCHEMBL24006263 | 0.78 | TSHR (0.48) | TEAD3TSHRSMN1; SMN2HTTHRH4 | |
| SCHEMBL9514785 | 0.78 | HDAC1 (0.57) | SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL291194 | 0.78 | SMN1; SMN2 (0.57) | TEAD3TSHRSMN1; SMN2HTTEPHX2 | |
| SCHEMBL12992809 | 0.77 | TEAD3 (0.56) | TEAD3TSHRSMN1; SMN2HTTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086644-A1 | CEREBLON LIGANDS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20100003732-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 2-SUBSTITUTED PROPANAL DERIVATIVE | KANEKA CORPORATION (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-1887085-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 2-SUBSTITUTED PROPANAL DERIVATIVE | Kaneka Corporation (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CHEMRX ADVANCED TECHNOLOGIES, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001040193-A1 | METHOD FOR THE SYNTHESIS OF PYRAZOLINES | CHEMRX ADVANCED TECHNOLOGIES, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CYP2F1, CYP2E1, CYP3A7 | TEAD3 2297/4885TSHR 3175/4885SMN1; SMN2 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.